StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$251.41+0.62 (+0.25%)

Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –

Biogen operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Biogen's operating cash flow for the twelve months ending Sep 30, 2026 was $2.25B, down 8.4% year over year. For fiscal 2025 it was $2.20B, down 23.3% from the year before. Over ten years it grew -5.6% a year on average. The highest annual figure on record is $7.08B in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.20B-23.3%
FY2024Dec 31, 2024$2.88B+85.9%
FY2023Dec 31, 2023$1.55B+11.8%
FY2022Dec 31, 2022$1.38B-62.0%
FY2021Dec 31, 2021$3.64B-13.9%
FY2020Dec 31, 2020$4.23B-40.2%
FY2019Dec 31, 2019$7.08B+14.4%
FY2018Dec 31, 2018$6.19B+36.0%
FY2017Dec 31, 2017$4.55B-0.8%
FY2016Dec 31, 2016$4.59B+17.0%
FY2015Dec 31, 2015$3.92B+33.2%
FY2014Dec 31, 2014$2.94B+25.5%
FY2013Dec 31, 2013$2.35B+24.7%
FY2012Dec 31, 2012$1.88B+8.8%
FY2011Dec 31, 2011$1.73B+6.3%
FY2010Dec 31, 2010$1.62B+51.1%
FY2009Dec 31, 2009$1.07B-31.2%
FY2008Dec 31, 2008$1.56B+53.4%
FY2007Dec 31, 2007$1.02B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$640.80M-49.6%
Q2 FY2026Jun 30, 2026$448.90M+179.0%
Q1 FY2026Mar 31, 2026$645.50M+148.9%
Q4 FY2025Dec 31, 2025$511.90M-32.7%
Q3 FY2025Sep 30, 2025$1.27B+36.0%
Q2 FY2025Jun 30, 2025$160.90M-74.3%
Q1 FY2025Mar 31, 2025$259.30M-53.1%
Q4 FY2024Dec 31, 2024$760.90M+5987.2%
Q3 FY2024Sep 30, 2024$935.60M+57.9%
Q2 FY2024Jun 30, 2024$625.80M+28.5%
Q1 FY2024Mar 31, 2024$553.20M+21.5%
Q4 FY2023Dec 31, 2023$12.50M–
Q3 FY2023Sep 30, 2023$592.40M-10.4%
Q2 FY2023Jun 30, 2023$487.00M-33.9%
Q1 FY2023Mar 31, 2023$455.30M+181.4%
Q4 FY2022Dec 31, 2022-$175.00M-120.9%
Q3 FY2022Sep 30, 2022$661.00M-17.9%
Q2 FY2022Jun 30, 2022$736.50M-40.0%
Q1 FY2022Mar 31, 2022$161.80M-79.0%
Q4 FY2021Dec 31, 2021$838.30M–
Q3 FY2021Sep 30, 2021$805.30M-31.8%
Q2 FY2021Jun 30, 2021$1.23B-37.0%
Q1 FY2021Mar 31, 2021$769.00M-47.6%
Q4 FY2020Dec 31, 2020-$367.10M-118.7%
Q3 FY2020Sep 30, 2020$1.18B-30.3%
Q2 FY2020Jun 30, 2020$1.95B-0.8%
Q1 FY2020Mar 31, 2020$1.47B+0.5%
Q4 FY2019Dec 31, 2019$1.96B+3.4%
Q3 FY2019Sep 30, 2019$1.69B-2.4%
Q2 FY2019Jun 30, 2019$1.96B+78.7%
Q1 FY2019Mar 31, 2019$1.46B+0.2%
Q4 FY2018Dec 31, 2018$1.90B+24.8%
Q3 FY2018Sep 30, 2018$1.74B+6.6%
Q2 FY2018Jun 30, 2018$1.10B-6.0%
Q1 FY2018Mar 31, 2018$1.46B+519.5%
Q4 FY2017Dec 31, 2017$1.52B-4.0%
Q3 FY2017Sep 30, 2017$1.63B–
Q2 FY2017Jun 30, 2017$1.17B–
Q1 FY2017Mar 31, 2017$235.20M–
Q4 FY2016Dec 31, 2016$1.58B–

More Biogen figures

See a number that looks wrong?